Moving a compound from proof-of-concept through clinical studies presents a number of challenges. Specialized capsules and encapsulation techniques can greatly simplify early studies, and play a critical role in meeting drug program timelines. Simple, scalable encapsulation solutions can further provide for rapid commercialization.

This webinar will review specialized capsules approaches and associated best practices developed by Capsugel product development teams:

Specialized capsules for clinical studies have been developed for rapid preclinical assessments, double-blind studies, and to allow capsule color decisions to be made later in the drug development process Capsugel Xcelodose®-based powder-in-capsule / microdosing studies have proven to reduce POC – phase II studies by up to 45% vs. traditional methods by eliminating excipient-related studies Liquid-filled hard capsule (LFHC) technology provides rapid POC and clinical evaluations across a wide range of challenging compounds, e.g. poorly soluble, highly potent, cytotoxics, proteins, peptides. Representative case studies demonstrating key aspects of these technologies will be discussed by Capsugel scientists.

Presented by:

  • Matt Richardson, Ph.D., Manager, Pharmaceutical Business Development, Capsugel
  • Jeffrey Williamson, Director, Preformulation/Formulation, Capsugel
  • By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

    Latest CHI content
    Latest briefing from the Knowledge Center